Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients ...Middle East

Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies PARIS, Feb. 24, 2023 /PRNewswire/ -- Servier, a global pharmaceutical company, today...

Hence then, the article about servier receives a positive chmp opinion for tibsovo in idh1 mutated acute myeloid leukemia aml and cholangiocarcinoma cca patients was published today ( Friday 24/02/2023 - 03:28 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients )

Also on site :

• Bowen Yang & Matt Rogers Gush About Lindsay Hubbard — and Reveal the Advice Amy Poehler Gave Them (Exclusive)
• IKEA Is Selling a Vibrant Blue Outdoor Cabinet That's Decluttering Patios in Style, and Shoppers 'Love It'
• Chappell Roan’s ‘Call Her Daddy’ Episode, KATSEYE, Young Miko & More Win at 2026 GLAAD Media Awards: Full Winners List